Ajay Major, MD, MBA
Gemyln George, MD
Dan Sherbenou, MD, PhD
Maria Amaya, MD, PhD
Jenna Moyer, MD
Terry Fry, MD
By the end of the review, attendees will be better equipped to:
Determine which patients with hematologic malignancy may benefit from specific targeted therapy
Recognize myriad of presentations of patients with hematologic illnesses
Identify higher-risk patients with hematologic malignancy and determine the best available therapies
Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers, etc.)
Manage complications of hematologic malignancies in an outpatient setting
Familiarize health care practitioners with the latest updates as per clinical trial data in the proper diagnosis and treatment of benign hematologic diseases, such as sickle cell anemia, coagulopathies, and autoimmune hemolytic anemias
Continuing Education Credit
CONTINUING MEDICAL EDUCATION
The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
CONTINUING NURSING EDUCATION
More information regarding CNE credit coming soon.